Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYC140 in Advanced Solid Tumors and Lymphoma
NCT05358379Phase 2Recruiting
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of plogosertib in bladder cancer, triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), sponsored by Cyclacel Pharmaceuticals, Inc.. Started Apr 2022; status: recruiting.
02
Drugs
plogosertib
03
Conditions
bladder cancertriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05358379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358379.